A significant decrease in anogenital warts incidence following the implementation of a national human papillomavirus immunization program in Israel.

Background Israel's National Immunization Program (NIP) for human papillomavirus (HPV) began in 2013 for 13-year-old girls with the 2-valent vaccine (2vHPV), switched to the 4-valent vaccine (4vHPV) in 2014, expanded to a gender-neutral (GNV) program in 2015, and adopted the 9-valent vaccine (9vHPV)... View More